Latest Intelligence on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Allergies: nothing to sneeze at

The continuing rise in the prevalence of allergic diseases, such as asthma, allergic rhinitis and eczema, will place considerable strain on the NHS in the UK. Insufficient numbers of allergy specialists and inadequate allergy training in medical schools will severely restrict access to disease modifying treatments like immune therapy.<BR />

Published By Datamonitor
26 Jun 2003
CommentWire
CommentWire

Alzheimer's disease: has NICE finally lived up to its name?

Published By Datamonitor
23 Jan 2001
Expert View
Expert View

Alzheimer's disease: physicians do not always practice what NICE preaches

The UK government's drug watchdog NICE has received a lot of publicity recently after publishing guidelines restricting the prescription of certain cognitive enhancers for Alzheimer's disease for reasons of cost. However, a recent survey of 181 neurologists by Datamonitor indicates that the NICE cost-benefit methodology may not reflect how the drug is actually used in the clinical setting.

Published By Datamonitor
05 Feb 2007
CommentWire
CommentWire

Antibacterials: narrow-spectrum strategy could change market

Researchers from the Royal Free Hospital have found that cutting down the use of broad spectrum antimicrobial agents can lead to a reduction in infections caused by Clostridium difficile. A wider adoption of this approach could reduce the market potential for broad spectrum agents significantly.

Published By Datamonitor
28 Mar 2007
ResearchWire
ResearchWire

Anticonvulsants: potential sales growth in off-label expansion

Published By Datamonitor
31 Jul 2001
CommentWire
CommentWire

Antidepressants: all is not well

Clever marketing and media coverage has helped to de-stigmatize depression. Diagnosis rates have soared and UK antidepressant prescriptions have doubled in the last 10 years. However, there are concerns over their effectiveness and safety. Drug companies need to overcome these concerns if they are to benefit from the rising demand.

Published By Datamonitor
01 Mar 2002
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001
CommentWire
CommentWire

Antidepressants: the questions continue

The expert panel assembled to review the safety of SSRIs, used in the treatment of depression, has been dissolved and a new team will be appointed. The decision means further delays for the results of the study and ongoing questions as to the safety of the SSRIs.

Published By Datamonitor
02 Apr 2003
CommentWire
CommentWire

Antidepressants: UK panel to review suicide link

Following claims that SSRIs can induce suicidal feelings, the Committee on Safety of Medicines has assembled an expert panel to review the safety of this drug class, which is used in the treatment of depression. The results of the study could mean new labeling rules and tighter controls on new products for the SSRI market.

Published By Datamonitor
10 Jan 2003
ResearchWire
ResearchWire

Antimetabolites: market will be worth $1.9 billion in 2007

Published By Datamonitor
12 Jun 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.